CemiplimAb-rwlc Survivorship and Epidemiology (CASE): A Prospective, Non-Interventional Study of the Safety and Effectiveness of Cemiplimab in Immunocompromised/Immunosuppressed Patients With Advanced Cutaneous Squamous Cell Carcinoma at 2 Years’ Follow-Up. J of Skin [Internet]. 2026 Mar. 10 [cited 2026 May 2];10(2):s756. Available from: https://skin.dermsquared.com/skin/article/view/4093